Minimal Clinically Important Difference for Safe and Simple Novel Acute Ischemic Stroke Therapies [Clinical Sciences]

Conclusions—Stroke expert responses to MCID surveys are affected by anchoring and centrality bias. When survey design takes these into account, the expert-derived MCID for a safe acute ischemic stroke treatment is 1.1% to 1.5%, in accord with actual physician behavior in guideline writing and clinical practice. This revised MCID value can guide clinical trial design and grant-funding and regulatory agency decisions.
Source: Stroke - Category: Neurology Authors: Tags: Ischemic Stroke, Neuroprotectants Original Contributions Source Type: research